Review



pp5 antibody c 20  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology pp5 antibody c 20
    Fig. 3. <t>PP5</t> mediates palbociclib-induced AMPK activation, autophagy, and apoptosis. (A) PP5 overexpression suppresses the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were transfected with vector or DDK-PP5 for 24 h and treated with palbociclib (15 lM) for another 24 h. (B) Pretreatment with arachidonic acid (AA), a PP5 activator, reversed the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were pretreated with AA (100 lM) for 4 h and then treated with palbociclib for 24 h. Autophagy was determined by LC3 immunoblotting. Apoptotic cells were measured by flow cytometry. *P < 0.05. (C) PP5 activity in Hep3B and PLC5 cells. (D) Palbociclib inhibits PP5 activity in PP5-containing Hep3B lysate. (E) Palbociclib suppresses activity of GST-PP5. Cantharidin, a known Ser/Thr phosphatase inhibitor, served as a positive control. *P < 0.05
    Pp5 Antibody C 20, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp5+antibody+c+20/PP5+Antibody/pm28453226-42-0-20
    Average 92 stars, based on 38 article reviews
    pp5 antibody c 20 - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner."

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.

    Journal: Molecular oncology

    doi: 10.1002/1878-0261.12072

    Fig. 3. PP5 mediates palbociclib-induced AMPK activation, autophagy, and apoptosis. (A) PP5 overexpression suppresses the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were transfected with vector or DDK-PP5 for 24 h and treated with palbociclib (15 lM) for another 24 h. (B) Pretreatment with arachidonic acid (AA), a PP5 activator, reversed the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were pretreated with AA (100 lM) for 4 h and then treated with palbociclib for 24 h. Autophagy was determined by LC3 immunoblotting. Apoptotic cells were measured by flow cytometry. *P < 0.05. (C) PP5 activity in Hep3B and PLC5 cells. (D) Palbociclib inhibits PP5 activity in PP5-containing Hep3B lysate. (E) Palbociclib suppresses activity of GST-PP5. Cantharidin, a known Ser/Thr phosphatase inhibitor, served as a positive control. *P < 0.05
    Figure Legend Snippet: Fig. 3. PP5 mediates palbociclib-induced AMPK activation, autophagy, and apoptosis. (A) PP5 overexpression suppresses the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were transfected with vector or DDK-PP5 for 24 h and treated with palbociclib (15 lM) for another 24 h. (B) Pretreatment with arachidonic acid (AA), a PP5 activator, reversed the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were pretreated with AA (100 lM) for 4 h and then treated with palbociclib for 24 h. Autophagy was determined by LC3 immunoblotting. Apoptotic cells were measured by flow cytometry. *P < 0.05. (C) PP5 activity in Hep3B and PLC5 cells. (D) Palbociclib inhibits PP5 activity in PP5-containing Hep3B lysate. (E) Palbociclib suppresses activity of GST-PP5. Cantharidin, a known Ser/Thr phosphatase inhibitor, served as a positive control. *P < 0.05

    Techniques Used: Activation Assay, Over Expression, Transfection, Plasmid Preparation, Western Blot, Cytometry, Activity Assay, Positive Control

    Fig. 5. In vivo effects of palbociclib in Huh7 xenograft nude mice. (A,B) Palbociclib suppresses Huh7 xenograft tumor growth and weight. Nude mice were subcutaneously implanted with 5 9 106 Huh7 cells. The mice received vehicle or palbociclib (150 mgkg1) orally every three days. The tumor area was measured twice a week. At the end of treatment, the tumors were harvested and the tumor weights were determined before lysis. Points/bars, mean (n = 5); bars, SD. **P < 0.01. (C) Western blot analysis of pAMPK, AMPK, and LC3 in Huh7 tumors. (D) PP5 activity in Huh7 tumors. *P < 0.05.
    Figure Legend Snippet: Fig. 5. In vivo effects of palbociclib in Huh7 xenograft nude mice. (A,B) Palbociclib suppresses Huh7 xenograft tumor growth and weight. Nude mice were subcutaneously implanted with 5 9 106 Huh7 cells. The mice received vehicle or palbociclib (150 mgkg1) orally every three days. The tumor area was measured twice a week. At the end of treatment, the tumors were harvested and the tumor weights were determined before lysis. Points/bars, mean (n = 5); bars, SD. **P < 0.01. (C) Western blot analysis of pAMPK, AMPK, and LC3 in Huh7 tumors. (D) PP5 activity in Huh7 tumors. *P < 0.05.

    Techniques Used: In Vivo, Lysis, Western Blot, Activity Assay

    Fig. 6. Expression of PP5 in human HCC tissues. (A) Expression of PP5 in HCC tumors and normal liver tissue. The protein expressions of PP5 in the HCC tumors and its adjacent normal part were analyzed in 153 patients with HCC by IHC. Representative images were shown here. (B) PP5 expression in HCC tumors is significantly higher in HCC tumors than in normal liver tissue. The expressions of PP5 were quantified by H-score and compared by Student’s t-test. P < 0.001. Bar, mean; error bar, SE. ***P < 0.001. (C) PP5 expression in paired tumor and normal liver tissue. Each dot represented the H-score obtained from indicated tissues, and each line linked an individual patient.
    Figure Legend Snippet: Fig. 6. Expression of PP5 in human HCC tissues. (A) Expression of PP5 in HCC tumors and normal liver tissue. The protein expressions of PP5 in the HCC tumors and its adjacent normal part were analyzed in 153 patients with HCC by IHC. Representative images were shown here. (B) PP5 expression in HCC tumors is significantly higher in HCC tumors than in normal liver tissue. The expressions of PP5 were quantified by H-score and compared by Student’s t-test. P < 0.001. Bar, mean; error bar, SE. ***P < 0.001. (C) PP5 expression in paired tumor and normal liver tissue. Each dot represented the H-score obtained from indicated tissues, and each line linked an individual patient.

    Techniques Used: Expressing

    Related Articles

    Western Blot:

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK 4/6‐independent manner
    Article Snippet: Palbociclib (Cat. No. HY‐50767A) purchased from MedChem Express was used for in vivo testing. .. PP5 antibody (C‐20) (sc‐32588) was used for immunoblotting, and the PP5 antibody (H‐7) (sc‐271816) used for immunoprecipitation was obtained from Santa Cruz Biotechnology (San Diego, CA, USA). .. Purified mouse anti‐PP5 antibody (611020) for the immunohistochemistry experiments was from BD Transduction Laboratories (San Jose, CA, USA).

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
    Article Snippet: Palbociclib (Cat. No. HY50767A) purchased from MedChem Express was used for in vivo testing. .. PP5 antibody (C-20) (sc-32588) was used for immunoblotting, and the PP5 antibody (H-7) (sc271816) used for immunoprecipitation was obtained from Santa Cruz Biotechnology (San Diego, CA, USA). .. Purified mouse anti-PP5 antibody (611020) for the immunohistochemistry experiments was from BD Transduction Laboratories (San Jose, CA, USA).

    Immunoprecipitation:

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK 4/6‐independent manner
    Article Snippet: Palbociclib (Cat. No. HY‐50767A) purchased from MedChem Express was used for in vivo testing. .. PP5 antibody (C‐20) (sc‐32588) was used for immunoblotting, and the PP5 antibody (H‐7) (sc‐271816) used for immunoprecipitation was obtained from Santa Cruz Biotechnology (San Diego, CA, USA). .. Purified mouse anti‐PP5 antibody (611020) for the immunohistochemistry experiments was from BD Transduction Laboratories (San Jose, CA, USA).

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
    Article Snippet: Palbociclib (Cat. No. HY50767A) purchased from MedChem Express was used for in vivo testing. .. PP5 antibody (C-20) (sc-32588) was used for immunoblotting, and the PP5 antibody (H-7) (sc271816) used for immunoprecipitation was obtained from Santa Cruz Biotechnology (San Diego, CA, USA). .. Purified mouse anti-PP5 antibody (611020) for the immunohistochemistry experiments was from BD Transduction Laboratories (San Jose, CA, USA).



    Similar Products

    pp5 antibody c 20  (Santa Cruz Biotechnology)
    92
    Santa Cruz Biotechnology pp5 antibody c 20
    Fig. 3. <t>PP5</t> mediates palbociclib-induced AMPK activation, autophagy, and apoptosis. (A) PP5 overexpression suppresses the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were transfected with vector or DDK-PP5 for 24 h and treated with palbociclib (15 lM) for another 24 h. (B) Pretreatment with arachidonic acid (AA), a PP5 activator, reversed the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were pretreated with AA (100 lM) for 4 h and then treated with palbociclib for 24 h. Autophagy was determined by LC3 immunoblotting. Apoptotic cells were measured by flow cytometry. *P < 0.05. (C) PP5 activity in Hep3B and PLC5 cells. (D) Palbociclib inhibits PP5 activity in PP5-containing Hep3B lysate. (E) Palbociclib suppresses activity of GST-PP5. Cantharidin, a known Ser/Thr phosphatase inhibitor, served as a positive control. *P < 0.05
    Pp5 Antibody C 20, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp5+antibody+c+20/PP5+Antibody/pm28453226-42-0-20
    Average 92 stars, based on 1 article reviews
    pp5 antibody c 20 - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3. PP5 mediates palbociclib-induced AMPK activation, autophagy, and apoptosis. (A) PP5 overexpression suppresses the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were transfected with vector or DDK-PP5 for 24 h and treated with palbociclib (15 lM) for another 24 h. (B) Pretreatment with arachidonic acid (AA), a PP5 activator, reversed the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were pretreated with AA (100 lM) for 4 h and then treated with palbociclib for 24 h. Autophagy was determined by LC3 immunoblotting. Apoptotic cells were measured by flow cytometry. *P < 0.05. (C) PP5 activity in Hep3B and PLC5 cells. (D) Palbociclib inhibits PP5 activity in PP5-containing Hep3B lysate. (E) Palbociclib suppresses activity of GST-PP5. Cantharidin, a known Ser/Thr phosphatase inhibitor, served as a positive control. *P < 0.05

    Journal: Molecular oncology

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.

    doi: 10.1002/1878-0261.12072

    Figure Lengend Snippet: Fig. 3. PP5 mediates palbociclib-induced AMPK activation, autophagy, and apoptosis. (A) PP5 overexpression suppresses the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were transfected with vector or DDK-PP5 for 24 h and treated with palbociclib (15 lM) for another 24 h. (B) Pretreatment with arachidonic acid (AA), a PP5 activator, reversed the effect of palbociclib on pAMPKa, autophagy, and apoptosis. Hep3B cells were pretreated with AA (100 lM) for 4 h and then treated with palbociclib for 24 h. Autophagy was determined by LC3 immunoblotting. Apoptotic cells were measured by flow cytometry. *P < 0.05. (C) PP5 activity in Hep3B and PLC5 cells. (D) Palbociclib inhibits PP5 activity in PP5-containing Hep3B lysate. (E) Palbociclib suppresses activity of GST-PP5. Cantharidin, a known Ser/Thr phosphatase inhibitor, served as a positive control. *P < 0.05

    Article Snippet: PP5 antibody (C-20) (sc-32588) was used for immunoblotting, and the PP5 antibody (H-7) (sc271816) used for immunoprecipitation was obtained from Santa Cruz Biotechnology (San Diego, CA, USA).

    Techniques: Activation Assay, Over Expression, Transfection, Plasmid Preparation, Western Blot, Cytometry, Activity Assay, Positive Control

    Fig. 5. In vivo effects of palbociclib in Huh7 xenograft nude mice. (A,B) Palbociclib suppresses Huh7 xenograft tumor growth and weight. Nude mice were subcutaneously implanted with 5 9 106 Huh7 cells. The mice received vehicle or palbociclib (150 mgkg1) orally every three days. The tumor area was measured twice a week. At the end of treatment, the tumors were harvested and the tumor weights were determined before lysis. Points/bars, mean (n = 5); bars, SD. **P < 0.01. (C) Western blot analysis of pAMPK, AMPK, and LC3 in Huh7 tumors. (D) PP5 activity in Huh7 tumors. *P < 0.05.

    Journal: Molecular oncology

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.

    doi: 10.1002/1878-0261.12072

    Figure Lengend Snippet: Fig. 5. In vivo effects of palbociclib in Huh7 xenograft nude mice. (A,B) Palbociclib suppresses Huh7 xenograft tumor growth and weight. Nude mice were subcutaneously implanted with 5 9 106 Huh7 cells. The mice received vehicle or palbociclib (150 mgkg1) orally every three days. The tumor area was measured twice a week. At the end of treatment, the tumors were harvested and the tumor weights were determined before lysis. Points/bars, mean (n = 5); bars, SD. **P < 0.01. (C) Western blot analysis of pAMPK, AMPK, and LC3 in Huh7 tumors. (D) PP5 activity in Huh7 tumors. *P < 0.05.

    Article Snippet: PP5 antibody (C-20) (sc-32588) was used for immunoblotting, and the PP5 antibody (H-7) (sc271816) used for immunoprecipitation was obtained from Santa Cruz Biotechnology (San Diego, CA, USA).

    Techniques: In Vivo, Lysis, Western Blot, Activity Assay

    Fig. 6. Expression of PP5 in human HCC tissues. (A) Expression of PP5 in HCC tumors and normal liver tissue. The protein expressions of PP5 in the HCC tumors and its adjacent normal part were analyzed in 153 patients with HCC by IHC. Representative images were shown here. (B) PP5 expression in HCC tumors is significantly higher in HCC tumors than in normal liver tissue. The expressions of PP5 were quantified by H-score and compared by Student’s t-test. P < 0.001. Bar, mean; error bar, SE. ***P < 0.001. (C) PP5 expression in paired tumor and normal liver tissue. Each dot represented the H-score obtained from indicated tissues, and each line linked an individual patient.

    Journal: Molecular oncology

    Article Title: Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.

    doi: 10.1002/1878-0261.12072

    Figure Lengend Snippet: Fig. 6. Expression of PP5 in human HCC tissues. (A) Expression of PP5 in HCC tumors and normal liver tissue. The protein expressions of PP5 in the HCC tumors and its adjacent normal part were analyzed in 153 patients with HCC by IHC. Representative images were shown here. (B) PP5 expression in HCC tumors is significantly higher in HCC tumors than in normal liver tissue. The expressions of PP5 were quantified by H-score and compared by Student’s t-test. P < 0.001. Bar, mean; error bar, SE. ***P < 0.001. (C) PP5 expression in paired tumor and normal liver tissue. Each dot represented the H-score obtained from indicated tissues, and each line linked an individual patient.

    Article Snippet: PP5 antibody (C-20) (sc-32588) was used for immunoblotting, and the PP5 antibody (H-7) (sc271816) used for immunoprecipitation was obtained from Santa Cruz Biotechnology (San Diego, CA, USA).

    Techniques: Expressing